Y-Site Compatibility Wall Charts Updated for 2020 King Guide Y-Site Compatibility Wall Charts include 123 IV drugs in 4 infusion fluids. Critical Care Admixtures We added 'Oxytocin' Updated with compatibility data published in the King Guide to Parenteral Admixtures for 2019 Available in English or French Laminated 27" x 27" poster Chemotherapy Admixtures Updated with compatibility data published in the King Guide to Parenteral Admixtures for 2019 Available in English Laminated 27" x 27" poster
In this update we added a new drug monograph for DALBAVANCIN. We added new stability information to the existing drug monographs for AMIODARONE HYDROCHLORIDE, CARBOPLATIN, CEFAZOLIN SODIUM, CEFTAZIDIME, INFLIXIMAB, MEROPENEM, METHOTRIMEPRAZINE HYDROCHLORIDE, PIPERACILLIN and TAZOBACTAM, AND SODIUM THIOSULFATE. In addition, new compatibility information is reported for these drugs: ACETAMINOPHEN, AMPICILLIN SODIUM, AMPICILLIN SODIUM – SULBACTAM SODIUM, BLINATUMOMAB, CEFTAZIDIME, CLINDAMYCIN PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE PHOSPHATE, FENTANYL CITRATE, FOSPHENYTOIN SODIUM, FUROSEMIDE, HALOPERIDOL LACTATE, HYDROMORPHONE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE, KETOPROFEN, LIDOCAINE HYDROCHLORIDE, MAGNESIUM SULFATE, METRONIDAZOLE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, RASBURICASE, SUGAMMADEX, TOTAL PARENTERAL NUTRITION SOLUTIONS, VINCRISTINE SULFATE, and VORICONAZOLE.
Mobile Device Y-Site Compatibility 2019 Y-site Compatibility of Critical Care Admixtures Quickly confirm the advisability of mixing intravenous drugs and determine if more in-depth information is needed from full text monographs provided in the complete King® Guide to Parenteral Admixtures®. Designed to report y-site compatibility of intravenous drugs commonly administered to hospital, ER, in-home and hospice care patients. 122 IV Drugs and 4 Infusion Fluids